Emily
Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245181/
Berger JR. COVID-19 and the nervous system. J Neurovirol. 2020;26(2):143-148. doi:10.1007/s13365-020-00840-5
...
Discussion
Although only 3 months have elapsed since the onset of the COVID-19 pandemic, neurological disorders do not appear to be extraordinarily common. Headache is common. Whether the headache is the consequence of viral invasion remains uncertain. Myalgias are also common and may be accompanied by an increase in muscle enzymes suggestive of a myositis, but severe rhabdomyolysis remains rare. Stroke has occurred in a small percentage of patients and likely results from multiple underlying pathophysiologic mechanisms. Although encephalopathy is seen with severe illness, it may be explained by the accompanying metabolic abnormalities attending a cytokine storm rather than occurring from viral invasion of the brain, though rare cases of the latter seem to occur. As with other viral infections, a small number of patients are likely to experience autoimmune neurological disease, specifically AIDP and ADEM, in the wake of SARS-CoV-2 infection.